Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.49 |
| ▸ | CDK4 | P11802 | 6/20 | 0.49 |
| ▸ | CCND1 | P24385 | 6/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.46 |
| ▸ | CDK9 | P50750 | 4/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.46 |
| ▸ | CDK11A | Q9UQ88 | 4/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.44 |
| ▸ | CCR6 | P51684 | 7/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200307 | 0.91 | CDK4 (0.46) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6197281 | 0.90 | CDK4 (0.50) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6199176 | 0.89 | CDK2 (0.45) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6196776 | 0.89 | CDK4 (0.49) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6196820 | 0.89 | CDK4 (0.49) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6195868 | 0.88 | CDK4 (0.45) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6407842 | 0.88 | CDK4 (0.51) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6197860 | 0.88 | CDK2 (0.50) | CDK2CDK4CCND1CDK1CCNT1 | |
| Hydrochloric Acid SCHEMBL6218550 | 0.88 | CDK4 (0.48) | CDK2CDK4CCND1CDK1CCNT1 | |
| SCHEMBL6194364 | 0.87 | CDK4 (0.50) | CDK2CDK4CCND1CDK1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1597256-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | PFIZER INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004074283-A1 | N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101595-A1 | N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use | CCNI, MKI67, TK1 | CDK2 6/4885CDK4 78/4885CCND1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.